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No previous studies have determined the phannaco- 
dynamics of intravenous procainamids when admin- 
isteredkra~of15mg/kgandatarateof50 
mg/min, as is common practice during ekctrophar- 
macokgk testing. In this study, 30 patients re- 
ceived procainamkie In this fashion; the rigM ven- 
trkular effactive refractory period and ths QRS ch~- 
ration at a ventrkular pacing rate of 120Iminute 
were then determined every minute for 20 minutes. 
Ten patients received no maintenance infuskn of 
procainamkk (group A), 10 received a 4 mg/min 
maintenance infuskn (group B) and 10 received an 
8 mg/min maintenance infuskn (group C). Ten ad- 
ditional patients received no procainamids and 
served as control subjects (group D). The plasma 
procainamide wncentratkn was measured at 1, 5, 
lo,15 and 20 minutes after the loading dose was 
adminlstered. A stable plasma procainamide con- 
centratkn was not present In group A, B, or C until 
15 minutes after infuskn of the loading dose. The 
effective refractory period and QRS duration in- 
creased compared with baseline at 1 minute, de- 
creased between 1 and 10 minutes aml then re- 
mained essentially unchanged between 10 and 20 
minutes in all 3 treatment groups. concentration-ef- 
feet relation was linear in each treatment group. 
The plasma procainamide concentrations in group C 
were significantly greater than in group A; however, 
the effects on refractoriness and QftS duration were 
similar in both groups. These findirrgs indicate that 
with a pnxainamids dosing method cammonly usad 
during electrophannacologk testing, the plasma 
procainamide concentration decreases signifkantly 
during the first 15 minutes after the loading dose is 
administered; the effects of procainamids on ven- 
trkular refractoriness and conduction parallel the 
changes in the plasma procainamids concentration; 
and an 8 mg/min maintenance infusion of procain- 
amids results in higher plasma procalnamide con- 
centratkns without an associated increase in ven- 
tricular refractoriness or slowing of conduction. 
(Am J Cardiol 1988;81:93-98) 
I ntravenous procainamide has been used extensively 
to suppress the induction of ventricular tachycardia 
during electropharmacologic testingl-ll; the most com- 
monly used dose is 1 g or 15 mg/kg administered at a 
rate of 50 mg/min .lp3-11 In some electrophysiology lab- 
oratories a maintenance infusion of procainamide is 
not used,1-4p9-11 whereas in others a continuous mainte- 
nance infusion between 2 and 8 mg/min is used.5-8 
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However, no data are available on the electrophysio- 
logic effects of a maintenance infusion of procain- 
amide after the administration of a large loading dose. 
We determined the acute pharmacodynamics of intra- 
venous procainamide as it is commonly used during 
electropharmacologic testing. 
Methods 
Study design and rationale: There were 4 groups of 
10 patients each. In 3 of the groups, a 15 mg/kg dose of 
procainamide was administered at a rate of 50 mg/ 
min. These 3 groups of patients then received either 
no maintenance infusion of procainamide (group A), a 
maintenance infusion of 4 mg/min (group B) or a 
maintenance infusion of 8 mg/min (group C, Table I]. 
The effects of procainamide on right ventricular effec- 
tive refractory period and QRS duration were deter- 
mined before and every minute for 20 minutes after 
the administration of the loading dose of procain- 
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TABLE I Study Groups 
Procainamide Dose 
Group 




A 10 15 0 
B 10 15 4 
C IO 15 8 
D (control) 10 0 0 
amide. Plasma drug concentrations were determined 
at regular intervals during the 20-minute testing inter- 
val. The fourth group of patients (group D) served as a 
control and received no drug. 
QRS duration during ventricular pacing was used 
as an index of global intraventricular conduction. A 
pacing rate of 12O/min was used to detect procaina- 
mide’s rate-dependent effects on intraventricular con- 
duction. The testing interval was limited to 20 min- 
utes to minimize patient discomfort, and also because 
in clinical practice, drug testing with programmed 
ventricular stimulation is usually accomplished within 
20 minutes.13J4 A loading dose of 15 mg/kg at a rate of 
50 mg/min was used in this study because procain- 
amide commonly has been administered in this fash- 
ion in clinical practice during electrophysiologic test- 
ing.lv3-11 Ideal body weight was used to calculate the 
actual procainamide dose because procainamide does 
not distribute acutely to adipose tissue.13 The infusion 
rates of 0.4 and 8 mg/min were chosen to represent the 
usual range of infusion rates used in clinical practice. 
A control group was included in the study design to 
ascertain whether ventricular refractoriness and QRS 
duration change over time in the absence of drug. 
Characteristics of subjects: The subjects were re- 
cruited from a pool of patients who underwent an 
electrophysiologic study that was clinically indicated. 
Exclusion criteria included an elevated serum creati- 
nine concentration (>l.l mg/dl), a systolic blood pres- 
sure <lOO mm Hg or the previous administration of 
any antiarrhythmic drug during the electrophysiologic 
study. In addition, patients were excluded if the onset 
or termination of the QRS complexes during ventricu- 
lar pacing was not well demarcated in any of the fron- 
tal plane leads. 
There were 21 men and 19 women, and their mean 
age was 54 f 16 years (mean f standard deviation). 
Twenty patients had coronary artery disease, 5 had a 
dilated cardiomyopathy, 2 had mitral valve prolapse, 2 
had a hypertrophic cardiomyopathy and 11 had no 
structural heart disease. The mean serum creatinine 
concentration was 1.0 f 0.1 mg/dl. There were no 
significant differences between the 4 groups of pa- 
tients with regard to age, type of underlying heart dis- 
ease, left ventricular ejection fraction, ideal body 
weight or serum creatine concentration. 
Electrophysiologic testing protocol: Studies were 
performed in the fasting, unsedated state after in- 
formed consent was obtained. All electrophysiologic 
studies were performed at least 5 half-lives after dis- 
continuation of antiarrhythmic drug therapy. A qua- 
dripolar electrode catheter inserted through a femoral 
vein was positioned against the right ventricular apex. 
A stable catheter position with a pacing threshold of 
<0.6 mA was obtained under fluoroscopic guidance. A 
5Fr cannula in a femoral artery was used to continu- 
ously monitor the arterial pressure and for drawing 
blood samples. Leads V1, I and III and the intracardiac 
electrogram recorded at the right ventricular apex 
were displayed on an oscilloscope and recorded at a 
paper speed of 25 mm/s on a Siemens Elema Minograf 
7 recorder. When ventricular pacing at a rate of 120/ 
min was performed to assess QRS duration, leads I, II, 
III, aVR, aVL and aVF were recorded at a paper speed 
of 200 mm/s. A programmable stimulator (Bloom As- 
sociates, Ltd.) was used for pacing. The pacing stimu- 
li were twice the diastolic threshold and 2 ms in 
duration. 
Determination of right ventricular effective re- 
fractory period and QRS duration: The effective re- 
fractory period was determined using an 8-beat drive 
train at a rate of 120/min and a single extrastimulus 
(S,]. The intertrain interval was 3 seconds. The extra- 
stimulus was moved closer to the last beat of the drive 
train (S,] in lo-ms steps and the effective refractory 
period was defined as the longest SlS2 interval that 
failed to evoke a response. For the first determination 
of the effective refractory period, the initial S& inter- 
val was 350 ma In subsequent determinations of the 
effective refractory period, the initial S& interval was 
always 30 ms beyond the previous effective refractory 
period. In all patients the effective refractory period 
was determined in a uniform fashion, with the first 
SlS2 interval that did not evoke a response being con- 
sidered the effective refractory period. 
QRS duration was measured during ventricular 
pacing at a rate of 120/min. Measurements were taken 
from the frontal plane lead with the QRS complexes 
that had the most well-defined onset and termination. 
In each patient, all measurements of QRS duration 
were taken from the same lead. The intra- and interob- 
server reproducibility in the measurement of QRS du- 
ration was >95%. 
Drug testing protocol: In the baseline state, the 
right ventricular effective refractory period and QRS 
duration at a ventricular pacing rate of 120/min were 
determined 5 times. The means of these 5 determina- 
tions were used as the baseline effective refractory 
period and QRS duration in each patient. Procain- 
amide was then administered intravenously at a dose 
of 15 mg/kg ideal body weight. Ideal body weight was 
estimated using the 1983 Metropolitan Life Insurance 
height and weight table. The infusion rate was 50 mg/ 
min. If the systolic blood pressure decreased to <95 
mm Hg during the infusion of the loading dose, the 
infusion was discontinued and the patient was exclud- 
ed from the study. Upon completion of administration 
of the loading dose, group A patients did not receive a 
maintenance infusion, group B patients received a 
maintenance infusion of 4 mg/min of procainamide 
and group C patients received an 8 mg/min infusion. 
After administration of the loading dose was complet- 
TABLE ii Plasma Procainamide Concentrations 
Plasma Procainamide Concentration (mglliter) 
Minute* Group A Group B Group c 
1 15.6 f 3.2+ 16.7 f 3.7 17.2 f 3.9 
5 10.1 f 2.5 10.7 f 2.3 72.2 f 2.0 
IO 8.6 f 2.2 9.1 f 7.8 11.2 f 7.9 
15 7.5 f 1.7 6.4 f 1.8 10.6 f 7.6 
20 7.0 f 1.7 8.0 f 1.8 10.2 f 1.6 
* Number of minutes after infusion of the loading dose of procainamide. 
+ Mean f 7 standard deviation. 
ed, the right ventricular effective refractory period 
and QRS duration were determined every minute for 
20 minutes. 
In the control group, no drug was infused. After the 
baseline determinations of effective refractory period 
and QRS duration, there was a 15-minute rest period, 
to simulate the period of drug administration in the 
treatment groups. The effective refractory period and 
QRS duration were then determined every minute for 
20 minutes. 
Determination of plasma drug concentrations: Ar- 
terial blood samples for determination of the plasma 
procainamide and N-ace@ procainamide concentra- 
tions were obtained at 1,5,10,15 and 20 minutes after 
administration of the loading dose of procainamide 
was completed. The plasma concentrations of procain- 
amide and N-acetyl procainamide were determined 
by reverse phase high performance liquid chromatog- 
raphy.15 Because the plasma N-acetyl procainamide 
concentrations were negligible in all treatment groups, 
these data are not presented in the results. 
Statistical analysis: The plasma procainamide con- 
centrations, the effective refractory periods and the 
QRS duration were compared statistically using a re- 
peated measures analysis of variance to determine 
treatment effects and time effects. Multiple compari- 
sons were performed using Fisher’s least significant 
difference procedure. Concentration-effect relations 
were determined by analysis of covariance. A p value 
<0.05 was considered significant. 
Results 
Plasma procainamide concentrations: The mean 
procainamide loading dose was 965 f 98 mg. The 
mean plasma procainamide concentrations in the 3 
treatment groups are listed in Table II and shown in 
Figure 1. Comparing the overall mean plasma procain- 
amide concentrations averaged over time in the 3 
treatment groups, there was a significant difference 
only between groups A and C (p <0.02). The difference 
in the plasma procainamide concentration between 
groups A and C was not significant at 1 or 5 minutes but 
was significant at lo,15 and 20 minutes after infusion 
of the loading dose. 
There was a significant time effect on the plasma 
procainamide concentration in each of the 3 treatment 
groups (p <O.OOl]. The largest decrease in the plasma 
procainamide concentration occurred between 1 and 5 
minutes after infusion of the loadinn dose. The maeni- 
TABLE iii Right Ventricular Effective Refractory Periods 
Effective Refractory Period (ms) 
Minute’ Group A Group 0 Group c Group D 
Baseline 223f 78 218f20 237f 76 228f 16 
1 261% 24 256f28 272f24 238f 77 
2 254f 25 257f28 267f27 235f 10 
3 250% 24 252f37 264f 78 231 f 78 
4 245f27 252f26 264% 79 231 f 22 
5 247f22 251f31 266f 20 231 f 21 
6 249f18 250f31 265621 231 f 20 
7 247f 18 240i28 263% 20 232f27 
8 249s 20 246f25 262f20 234i22 
9 248f21 245% 29 263f 16 234f20 
70 246f27 244f 26 260f 18 233f 79 
11 245f 77 245f 29 259f 76 233f 10 
72 243f 19 244f 27 260f 20 230f78 
13 246f 21 245f28 262% 17 237 hi8 
74 244f 78 240f27 262% 19 231f18 
75 244f 23 245f28 262% 18 232f 75 
16 243% 21 244f26 267 f18 233f 75 
17 244f 18 242f 25 262i 78 237 f15 
18 243% 78 245f25 262f 78 230% 19 
79 244f 10 242f25 260f 13 220i 15 
20 241f20 243f 27 258f17 230f 78 
l Number of minutes after infusion of the loadlng dose of procainamide. 
Data are mean f standard deviatlon. 
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tude of the decline in plasma procainamide concentra- 
tion between 5 and 20 minutes ranged from a mean of 
2.0 to 3.1 mg/l. Within each treatment group, multiple 
comparisons of the mean plasma procainamide con- 
centration at various times demonstrated that only the 
means at 15 and 20 minutes did not differ significantly 
from each other. A post hoc comparison demonstrated 
that the decrease in the plasma procainamide concen- 
tration between minutes 1 and 20 was greater in mag 
nitude in groups A and B than in group C (p <0.05). 
Right ventricular effective refractory periods: The 
right ventricular effective refractory periods are listed 
in Table III. The mean effective refractory periods at 
selected points in time are shown in Figure 2. 
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FIGURE 1. Mean plasma procainamide (PA) concentrations in the 3 
treatment groups, each of which received a loading dose of 15 mg/ 
kg. Each group consisted of 10 patients. The mean plasma procain- 
amide concentrations in the group that received a maintenance 
infusion of 8 mg/min were significantly gr 
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The overall mean effective refractory periods aver- 
aged over time in each of the 3 treatment groups were 
each significantly greater than the mean effective re- 
fractory period in the control group (p <O.OZ). Compar- 
ing the 3 treatment groups, there were no significant 
differences in the overall mean effective refractory 
periods averaged over time. 
The control group did not show a significant change 
in effective refractory period over time (p = 0.2). There 
was a significant time effect in each of the 3 treatment 
groups (p <O.OOl). There was a significant increase 
over baseline in the effective refractory period in each 
of the treatment groups at 1 minute after infusion of the 
procainamide loading dose; the effective refractory 
periods decreased between 1 and 10 minutes, then 
remained essentially unchanged between 10 and 20 
minutes after infusion of the procainamide loading 
dose. 
There was a linear concentration-effect relation in 
each of the 3 treatment groups and no significant dif- 
ferences between the 3 groups in the slopes of the 
regression equations. There was not a significant inter- 
action between the 3 treatment groups and time (p = 
0.3), indicating that the time trends in groups A, B and 
C were parallel. 
QRS duration: The mean QRS durations are listed 
in Table IV. The mean QRS durations at selected 
points in time are shown in Figure 3. 
The mean baseline QRS durations in groups C and 
D were significantly greater than in groups A and B (p 
= 0.01). When corrected for the difference in the base- 
line QRS duration, there was not a significant differ- 
ence in the overall mean QRS durations averaged over 
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FIGURE 2. Mean rlght ventricular effective refractory periods FIGURE 3. The mean ORS duration at a ventricular pacing rate Of 
(RVERP) In the 3 treatment groups and the control group. The mean 120/mln In the 3 treatment groups and the control group. When 
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slgnlflcantly different from each other. PA = prooalnamlde. treatment groups and the control group. 
The control group did not show a significant change 
in QRS duration over time (p = 0.7). A significant time 
effect was present in each of the treatment groups [p 
<O.OOl). 
There was not a significant interaction between the 
treatment groups and time (p = 0.3), indicating that the 
time trends were parallel. The overall time trend con- 
sisted of a sharp increase over baseline in QRS dura- 
tion during the first minute after infusion of the 
procainamide loading dose, followed by a gradual de- 
crease up until 15 minutes, then a leveling off between 
15 and 20 minutes. There was a linear concentration- 
effect relation in each of the 3 treatment groups and no 
significant differences between the 3 groups in the 
slopes of the regression equations. 
Discussion 
Plasma procainamide concentrations: The find- 
ings of this study indicate that a common method used 
for administering intravenous procainamide during 
acute electropharmacologic testing (15 mg/kg at SO 
mg/min] results in a continuous decrease in the plas- 
ma procainamide concentration during the first 15 
minutes after the loading dose is administered. The 
decrease in the plasma procainamide concentration, 
however, is attenuated by the use of an 8 mg/min 
maintenance infusion of procainamide. The absence 
of a steady-state plasma procainamide concentration 
during the first 15 minutes after the relatively rapid 
administration of a large dose of procainamide is in 
keeping with the distribution half-life of intraven- 
ous procainamide, which has been estimated to be 5 
minutes.16 
Effects on ventricular refractoriness: The changes 
in the right ventricular effective refractory period that 
occurred after the administration of procainamide 
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concentration, with a linear concentration-effect rela- 
tion in each of the 3 treatment groups. 
Whereas an 8 mg/min maintenance infusion of 
procainamide resulted in higher plasma procainamide 
concentrations than when the loading dose was not 
followed by a maintenance infusion, the higher plas- 
ma procainamide concentrations were not associated 
with a greater degree of lengthening of the ventricular 
effective refractory period. Therefore, when a pro- 
cainamide loading dose is administered at a rate of 50 
mg/min, the tissue effect of procainamide on the ven- 
tricular effective refractory period may not be affected 
by the higher plasma concentrations that result from 
the use of an 8 mg/min infusion of procainamide. 
Effects on intraventricular conduction: Changes 
over time in the QRS duration at a ventricular pacing 
rate of 120/min, used as an index of global intraven- 
tricular conduction, paralleled the changes that oc- 
curred in ventricular refractoriness. When corrected 
for the baseline difference in QRS duration, the QRS 
durations during the 8 mg/min infusion of procain- 
amide did not differ from the QRS durations in the 
other 2 treatment groups. Therefore, as is the case with 
ventricular refractoriness, the effect of procainamide 
on intraventricular conduction between 5 and 20 min- 
utes after the loading dose has been administered does 
not appear to be affected by the use of a maintenance 
infusion of procainamide. 
Disposition of intravenous procainamide: The dis- 
position of procainamide after an intravenous infusion 
has been described as being consistent with a X-corn- 
partment model, with complete distribution from the 
plasma compartment into the central tissue compart- 
ment generally occurring within 30 minutes.17 In this 
type of model, it would be expected that the principal 
determinant of the tissue procainamide concentration 
during the first 20 minutes after the administration of a 
procainamide loading dose would be the distribution 
that occurs from the plasma into the central compart- 
ment as procainamide is being infused at a rate of 50 
mg/min. This may explain why the use of an 8 mg/min 
maintenance infusion of procainamide did not signifi- 
cantly augment the electrophysiologic effects of pro- 
cainamide despite resulting in higher plasma pro- 
cainamide concentrations than in the absence of a 
maintenance infusion. 
Clinical implications: Based on a pharmacokinetic 
approach, it has been determined that a therapeutic 
plasma procainamide concentration can be achieved 
in less than 15 minutes in a patient with normal renal 
function if procainamide is administered in a loading 
dose of 0.22 mg/kg/min for 1 hour, followed by a main- 
tenance infusion of 2.8 mg/kg/hr.la However, approxi- 
mateIy 2 hours are required for steady-state conditions 
to be reached with this dosing method. A 2-hour wait- 
ing period is not feasible in patients undergoing elec- 
tropharmacologic testing. Therefore, standard practice 
has been to begin programmed stimulation either im- 
mediately or 5 minutes after the loading dose has been 
administered at a rate of 50 mg/min, and to measure 
the plasma procainamide concentration upon comple- 
tion of the stimulation protocol.*-I1 When reported, the 
TABLE IV QRS Durations at a Ventricular Paced Rate of 120/mln 
QRS Duration(ms) 
Minute* Group A Group0 GroupC GroupD 
Baseline 139 * 13 146f 21 158% 12 160f21 
1 173f 18 182f 29 198f 19 160f21 
2 170f 16 180s 27 196f 17 160f21 
3 170f 15 178f26 197f 14 16lf20 
4 168f 15 174f22 194% 15 160f20 
5 167f 13 175f22 192f 13 160f 22 
6 166% 14 172f21 192fl4 160% 22 
7 168% 18 172f21 189% 13 161f20 
8 168f18 170f20 190f12 160f22 
9 164f 15 17ozk20 190f 14 161f 21 
10 164f 18 169f 22 190f 14 160f21 
11 165f18 169f21 189f 13 160f 21 
12 161f17 168f22 189i14 159f22 
13 161fl8 168f 22 188f 15 16Oi21 
14 161f17 168% 22 188il5 159f20 
15 161f 17 166f21 186i 14 160f22 
16 160f 17 167f22 185f 14 160% 21 
17 180f 16 166622 186i 14 160f21 
18 159 f 16 168f22 186i 13 159f20 
19 158fl5 168f22 184i 14 159f 20 
20 158f16 167f22 184i 14 160f 22 
l Number of minutes after infusion of the loading dose of procainamida. 
interval required to complete the stimulation protocol 
has been described as usually being 5 to 15 minutes.13 
During this time period, there is a continual decrease 
in the plasma procainamide concentration and in its 
effects on ventricular refractoriness and conduction. 
This may create a limitation in determining the effec- 
tive plasma procainamide concentration relevant for 
long-term therapy. 
The decrease in plasma procainamide concentra- 
tions that occurs in the first 15 minutes is attenuated by 
the use of an 8 mg/min maintenance infusion of pro- 
cainamide. However, the use of a maintenance infu- 
sion may introduce an additional limitation. The main- 
tenance infusion may result in an increase in the plas- 
ma procainamide concentration without an associated 
increase in the effects of procainamide on ventricular 
conduction and refractoriness. This suggests that the 
effective plasma procainamide concentration may be 
overestimated. 
These limitations of acute drug testing may argue in 
favor of testing patients with oral procainamide in- 
stead of relying on the results of intravenous procain- 
amide testing to guide long-term therapy. 
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